Kairos Pharma, LTD.
KAPANYSE
$0.31
↓ -8.8%Jul 17 close · end-of-day
Price
1Y↓ -71.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.5M
Enterprise Value
$2.8M
P/E
—
P/S
—
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$5.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-109.9%
ROIC
-289.2%
Debt / Equity
—
Net Cash
$3.7M
Return 1Y
-69.6%
Company profile
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Our registered corporate address is 2355 Westwood Blvd., #139, Los Angeles, California.
- CEO
- John S. Yu
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- kairospharma.com
Management & directors
- Bhowmick NeilChief Scientific Officer
- Murali RamachandranVP of Research and Development
- Samuelson DougChief Financial Officer
- Yu John SCEO and Chairman
Roles derived from SEC Form 4 filings.
Earnings
KAPA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.080.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$1.7M | -$2.3M | -$5.6M |
| Net income | -$1.8M | -$2.6M | -$5.4M |
| Diluted EPS | -$0.17 | -$0.23 | -$0.30 |
| Operating cash flow | $81,000.00 | -$4.0M | -$3.4M |
| Free cash flow | — | — | — |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$222,000.00 | -$383,000.00 | -$1.5M | -$1.3M | -$1.5M | -$1.4M | -$1.4M | -$1.7M |
| Net income | -$253,000.00 | -$1.0M | -$980,000.00 | -$1.3M | -$1.4M | -$1.4M | -$1.4M | -$1.7M |
| Diluted EPS | -$0.02 | -$0.10 | -$0.08 | -$0.08 | -$0.08 | -$0.07 | -$0.07 | -$0.08 |
| Operating cash flow | -$168,000.00 | -$2.0M | -$1.8M | -$714,000.00 | -$805,000.00 | -$838,000.00 | -$1.1M | -$1.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Jul 2, 2026
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-08 | Bhowmick Neil· Chief Scientific Officer | Award | 171,756 | $0.00 | $0.00 | filing |
| 2025-10-08 | Bae Hyun W. | Award | 19,084 | $0.00 | $0.00 | filing |
| 2025-10-08 | Murali Ramachandran· VP of Research and Development | Award | 152,672 | $0.00 | $0.00 | filing |
| 2025-10-08 | Keyoung Hansoo Michael | Award | 19,084 | $0.00 | $0.00 | filing |
| 2025-10-08 | Singhvi Rahul | Award | 19,084 | $0.00 | $0.00 | filing |
| 2025-10-08 | Samuelson Doug· Chief Financial Officer | Award | 152,672 | $0.00 | $0.00 | filing |
| 2025-10-08 | Yu John S· CEO and Chairman | Award | 190,840 | $0.00 | $0.00 | filing |
| 2025-10-08 | Samuelson Doug· Chief Financial Officer | Award | 152,672 | $0.00 | $0.00 | filing |
| 2025-10-08 | Yu John S· CEO and Chairman | Award | 190,840 | $0.00 | $0.00 | filing |
| 2025-09-16 | Bae Hyun W. | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-09-16 | Keyoung Hansoo Michael | Award | 10,000 | $0.00 | $0.00 | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.